Abstract:The 18-electron half-sandwich platinum group (Rh, Ru, Ir, and Os) metal anticancer complexes have been largely reported due to their easy tunable structure, high potency toward cancer cells, and specific mechanism of actions. However, the 16-electron (without the leaving group Cl-) half-sandwich complexes and their biological evaluation are rarely investigated. With an easy access to the required alpha-keto-beta-diimine ligands using m-CPBA as oxidant, we herein reported the synthesis and characterization of a panel of structurally related 16-electron piano-stool rhodium, iridium, and ruthenium complexes through the rearranged coordination reaction. These complexes have been well-established by NMR spectroscopy, mass spectrometry, single-crystal X-ray crystallography, and elemental analysis. Each of these complexes was stable and exhibited fluorescence in solution. Although no reaction with nucleobase (9-EtG and 9-MeA) was observed, the representative Rh5 showed affinity toward CT-DNA. These 16-electron complexes showed promising activity toward A549 and HeLa cancer cells with the values of IC50 in the range 7.1-32.3 mu M, which was comparable to or even better than cisplatin. In addition, the structure-activity relationships were observed that the change of the metal center from iridium(III) and ruthenium(II) to rhodium(III) could enhance the cytotoxicity of these unsaturated complexes. The investigation of mechanism of actions (MoAs) using flow cytometry displayed that the cytotoxicity of the complex Rh5 was associated with the perturbation of the cell cycle and the induction of cell apoptosis. Moreover, microscopic analysis by confocal microscopy suggested that the representative 16-electron complex Rh5 entered A549 cells via energy-dependent pathway and predominantly accumulated in lysosomes, thus resulting in the disruption of lysosomal integrity.

Innenrücktitelbild: Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy (angew. Chem. 40/2018)

Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy

Natural Derivatives of Selective HDAC8 Inhibitors with Potent in Vivo Antitumor Efficacy Against Breast Cancer

A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 As an Epigenetic Modulator in Prostate Cancer Cells.

Theranostic Lysosomal Targeting Anticancer and Antimetastatic Agents: Half-Sandwich Iridium(III) Rhodamine Complexes

Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines

New triazole-based coordination complexes as antitumor agents against triple negative breast cancer MDA-MB-468 cell line

Innentitelbild: Peptide‐Conjugated Long‐Lived Theranostic Imaging for Targeting GRPr in Cancer and Immune Cells (angew. Chem. 41/2020)

Rhodium(I) Complexes Containing the N^N^N-Chelating Ligand: Synthesis, Structure, and Biological Activity

Titelbild: A Macromolecular Drug for Cancer Therapy via Extracellular Calcification (Angew. Chem. 12/2021)

Innenrücktitelbild: Bioinspired Therapeutic Dendrimers As Efficient Peptide Drugs Based on Supramolecular Interactions for Tumor Inhibition (angew. Chem. 14/2015)

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity

Pharmacological inhibition of KDM5A for cancer treatment

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Design, Synthesis and Biological Evaluation of Novel Dual-Acting Modulators Targeting Both Estrogen Receptor Α (erα) and Lysine-Specific Demethylase 1 (LSD1) for Treatment of Breast Cancer.

Ein Multitarget‐Gold(I)‐Komplex Induziert Zytotoxizität Im Zusammenhang Mit Aneuploidie in HCT‐116‐Kolorektalkarzinomzellen

Identification of a Rhodium(iii) Complex As a Wee1 Inhibitor Against TP53-mutated Triple-Negative Breast Cancer Cells.

Targeting Epigenetic Reader and Eraser: Rational Design, Synthesis and in Vitro Evaluation of Dimethylisoxazoles Derivatives As BRD4/HDAC Dual Inhibitors

A Liposome Encapsulated Ruthenium Polypyridine Complex As a Theranostic Platform for Triple-Negative Breast Cancer.

16-Electron Half-Sandwich Rhodium(III), Iridium(III), and Ruthenium(II) Complexes As Lysosome-Targeted Anticancer Agents

From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1h-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives As Agents for the Treatment of Triple Negative Breast Cancer